Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model

Drago Kuzman, Klementina Fon Tacer, M. Cerne, Tadeja Reen, Jure Aimovi, Urka Cegovnik, Darko Kocjan, Uros Urleb, Damjana Rozman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The poloxamer P-407 hyperlipidemia mouse is a genetically unaltered, nondiet-induced model of atherosclerosis which is useful in studying effects of lipid lowering drugs. While the model is relatively well described on the biochemical level, the knowledge regarding the global gene expression was lacking so far. As expected, the P-407 elevates plasma triglycerides and cholesterol. Using microarray analysis and RT-PCR we show for the first time that poloxamer triggers a concerted modulation of hepatic genes involved in multiple steps of atherogenesis, such as lipid metabolism, initiation of atherogenesis, lesion formation, and atheroma progression. 106 hepatic genes were upregulated and only 40 downregulated, suggesting that upregulation of atherogenic genes precedes the atheroma formation. Modulated expression of circadian genes has also been observed in this type of hyperlipidemia but further studies are needed to elucidate whether this effects the rhythm of animals.

Original languageEnglish (US)
Pages (from-to)262-269
Number of pages8
JournalActa Chimica Slovenica
Volume56
Issue number1
StatePublished - 2009

Fingerprint

Poloxamer
Genes
Modulation
Microarrays
Gene expression
Animals
Triglycerides
Cholesterol
Lipids
Plasmas
Pharmaceutical Preparations

Keywords

  • Atherogenesis
  • Circadian
  • Hyperlipidemia
  • Poloxamer

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Kuzman, D., Tacer, K. F., Cerne, M., Reen, T., Aimovi, J., Cegovnik, U., ... Rozman, D. (2009). Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model. Acta Chimica Slovenica, 56(1), 262-269.

Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model. / Kuzman, Drago; Tacer, Klementina Fon; Cerne, M.; Reen, Tadeja; Aimovi, Jure; Cegovnik, Urka; Kocjan, Darko; Urleb, Uros; Rozman, Damjana.

In: Acta Chimica Slovenica, Vol. 56, No. 1, 2009, p. 262-269.

Research output: Contribution to journalArticle

Kuzman, D, Tacer, KF, Cerne, M, Reen, T, Aimovi, J, Cegovnik, U, Kocjan, D, Urleb, U & Rozman, D 2009, 'Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model', Acta Chimica Slovenica, vol. 56, no. 1, pp. 262-269.
Kuzman D, Tacer KF, Cerne M, Reen T, Aimovi J, Cegovnik U et al. Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model. Acta Chimica Slovenica. 2009;56(1):262-269.
Kuzman, Drago ; Tacer, Klementina Fon ; Cerne, M. ; Reen, Tadeja ; Aimovi, Jure ; Cegovnik, Urka ; Kocjan, Darko ; Urleb, Uros ; Rozman, Damjana. / Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model. In: Acta Chimica Slovenica. 2009 ; Vol. 56, No. 1. pp. 262-269.
@article{f715dda96cae4d25ba9336f956d323aa,
title = "Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model",
abstract = "The poloxamer P-407 hyperlipidemia mouse is a genetically unaltered, nondiet-induced model of atherosclerosis which is useful in studying effects of lipid lowering drugs. While the model is relatively well described on the biochemical level, the knowledge regarding the global gene expression was lacking so far. As expected, the P-407 elevates plasma triglycerides and cholesterol. Using microarray analysis and RT-PCR we show for the first time that poloxamer triggers a concerted modulation of hepatic genes involved in multiple steps of atherogenesis, such as lipid metabolism, initiation of atherogenesis, lesion formation, and atheroma progression. 106 hepatic genes were upregulated and only 40 downregulated, suggesting that upregulation of atherogenic genes precedes the atheroma formation. Modulated expression of circadian genes has also been observed in this type of hyperlipidemia but further studies are needed to elucidate whether this effects the rhythm of animals.",
keywords = "Atherogenesis, Circadian, Hyperlipidemia, Poloxamer",
author = "Drago Kuzman and Tacer, {Klementina Fon} and M. Cerne and Tadeja Reen and Jure Aimovi and Urka Cegovnik and Darko Kocjan and Uros Urleb and Damjana Rozman",
year = "2009",
language = "English (US)",
volume = "56",
pages = "262--269",
journal = "Acta Chimica Slovenica",
issn = "1318-0207",
publisher = "Slovensko Kemijsko Drustvo",
number = "1",

}

TY - JOUR

T1 - Modulation of hepatic transcriptome in the poloxamer p-407 hyperlipidemia mouse model

AU - Kuzman, Drago

AU - Tacer, Klementina Fon

AU - Cerne, M.

AU - Reen, Tadeja

AU - Aimovi, Jure

AU - Cegovnik, Urka

AU - Kocjan, Darko

AU - Urleb, Uros

AU - Rozman, Damjana

PY - 2009

Y1 - 2009

N2 - The poloxamer P-407 hyperlipidemia mouse is a genetically unaltered, nondiet-induced model of atherosclerosis which is useful in studying effects of lipid lowering drugs. While the model is relatively well described on the biochemical level, the knowledge regarding the global gene expression was lacking so far. As expected, the P-407 elevates plasma triglycerides and cholesterol. Using microarray analysis and RT-PCR we show for the first time that poloxamer triggers a concerted modulation of hepatic genes involved in multiple steps of atherogenesis, such as lipid metabolism, initiation of atherogenesis, lesion formation, and atheroma progression. 106 hepatic genes were upregulated and only 40 downregulated, suggesting that upregulation of atherogenic genes precedes the atheroma formation. Modulated expression of circadian genes has also been observed in this type of hyperlipidemia but further studies are needed to elucidate whether this effects the rhythm of animals.

AB - The poloxamer P-407 hyperlipidemia mouse is a genetically unaltered, nondiet-induced model of atherosclerosis which is useful in studying effects of lipid lowering drugs. While the model is relatively well described on the biochemical level, the knowledge regarding the global gene expression was lacking so far. As expected, the P-407 elevates plasma triglycerides and cholesterol. Using microarray analysis and RT-PCR we show for the first time that poloxamer triggers a concerted modulation of hepatic genes involved in multiple steps of atherogenesis, such as lipid metabolism, initiation of atherogenesis, lesion formation, and atheroma progression. 106 hepatic genes were upregulated and only 40 downregulated, suggesting that upregulation of atherogenic genes precedes the atheroma formation. Modulated expression of circadian genes has also been observed in this type of hyperlipidemia but further studies are needed to elucidate whether this effects the rhythm of animals.

KW - Atherogenesis

KW - Circadian

KW - Hyperlipidemia

KW - Poloxamer

UR - http://www.scopus.com/inward/record.url?scp=65349096122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349096122&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65349096122

VL - 56

SP - 262

EP - 269

JO - Acta Chimica Slovenica

JF - Acta Chimica Slovenica

SN - 1318-0207

IS - 1

ER -